Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | NOS1 | P29475 | 4/20 | 0.58 |
| ▸ | NOS3 | P29474 | 3/20 | 0.58 |
| ▸ | NOS2 | P35228 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL22347074 | 0.86 | BLM (1.00) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Sulfuric Acid SCHEMBL317855 | 0.86 | BLM (1.00) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Sulfuric Acid SCHEMBL18206 | 0.86 | BLM (1.00) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Sulfuric Acid SCHEMBL29483831 | 0.83 | BLM (0.94) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Sulfuric Acid SCHEMBL21827141 | 0.80 | — | — | |
| SCHEMBL27962429 | 0.77 | KDM4E (0.71) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Ethylisothiourea SCHEMBL11693925 | 0.77 | NOS1 (0.65) | CYP2D6CYP2C19KDM4EBLMNPSR1 | |
| Bromide SCHEMBL27962443 | 0.76 | — | — | |
| Iodide SCHEMBL11696034 | 0.76 | — | — | |
| SCHEMBL78077 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | NOOGEN LLC (RU) | 2025-09-16 | — | — | US | disclosed |
| US-11596704-B2 | Process monitoring device | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-115010780-A | Modified oligonucleotide and preparation method thereof | 努根有限责任公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-106795197-B | Modified oligonucleotide and preparation method thereof | 努根有限责任公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11208430-B2 | Modified oligonucleotides and methods for their synthesis | NOOGEN LLC (RU) | 2021-12-28 | — | — | US | disclosed |
| EP-3904364-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | Noogen LLC (RU) | 2021-11-03 | — | — | EP | disclosed |
| CN-112851663-A | Fused heterocyclic compound and application thereof | 博瑞生物医药（苏州）股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112745335-A | Tri-heterocyclic compound and application thereof | 武汉誉祥医药科技有限公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3183260-B1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | NOOGEN LLC (RU) | 2021-03-31 | — | — | EP | disclosed |
| US-20210032283-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
| US-5273989-A | 3,5-disubstituted 2-isoxazolines and isoxazoles, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
| US-5143915-A | Hypotensive agents | E. R. SQUIBB & SONS, INC. (US) | 1992-09-01 | — | — | US | disclosed |
| US-4046884-A | N-(α-Aminoalkylidene)phosphor- and phosphonamidates, and method for controlling insects | VELSICOL CHEMICAL CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032283-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | RNGTT, TYMP, POLM | CYP2D6 3987/4885CYP2C19 4782/4885KDM4E 3964/4885 |
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | RNGTT, TYMP, POLM | CYP2D6 3987/4885CYP2C19 4782/4885KDM4E 3964/4885 |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | PHOSPHO1, G6PC1, PC | CYP2D6 1991/4885CYP2C19 1676/4885KDM4E 2877/4885 |
| US-11208430-B2 | Modified oligonucleotides and methods for their synthesis | TYMP, POLRMT, RNGTT | CYP2D6 3261/4885CYP2C19 4042/4885KDM4E 4431/4885 |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | CYP2D6 736/4885CYP2C19 408/4885KDM4E 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.